Cargando…
Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
BACKGROUND: Enzastaurin, an oral serine–threonine kinase inhibitor, was initially developed as an ATP-competitive selective inhibitor against protein kinase Cβ. However, the mechanism by which enzastaurin contributes to tumourigenesis remains unclear. METHODS: We analysed the anti-tumour effects of...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305973/ https://www.ncbi.nlm.nih.gov/pubmed/22333600 http://dx.doi.org/10.1038/bjc.2012.7 |